Yourgene Health PLC Launch of DPYD chemotoxicity diagnostic assay (6811M)
18 September 2019 - 4:00PM
UK Regulatory
TIDMYGEN
RNS Number : 6811M
Yourgene Health PLC
18 September 2019
Yourgene Health plc
("Yourgene" or the "Company")
Launch of DPYD chemotoxicity diagnostic assay
Test to identify cancer patients at risk of lethal side effects
from chemotherapy
Manchester, UK - 18 September 2019: Yourgene (AIM: YGEN), a
leading international molecular diagnostics group, announces the
launch of the Company's first oncology product, the Elucigene DPYD
assay ("Elucigene DPYD"), a new chemotoxicity diagnostic assay.
Elucigene DPYD is a simple-to-use genotyping test that can
identify cancer patients with Dihydropyrimidine Dehydrogenase (DPD)
deficiency, which can cause severe and sometimes lethal side
effects in patients being treated with chemotherapeutic drug
5-Fluorouracil (5-FU), commonly used in the treatment of colon,
oesophageal, stomach, pancreatic, breast and cervical cancers. 5-FU
is metabolized by the DPD enzyme which is encoded by the DPYD
gene.
An estimated two million people globally are treated with
fluoropyrimidines (including 5-FU) each year(1) , with between
10-30% of these patients suffering severe side effects associated
with DPD deficiency(2) , and up to 1% of patients treated with 5-FU
are estimated to die as a result of DPD deficiency(2) . Once
identified using genotyping treatment can be personalized for that
patient, potentially reducing the incidence of hospital admission
and preventing rare and unnecessary deaths associated with 5-FU
toxicity.
Elucigene DPYD conforms with the Clinical Pharmacogenetics
Consortium Guidelines, published in 2017 for DPYD genotyping, which
recommends testing for four clinically relevant mutations, which
are all covered by the Company's comprehensive test for six common
types of genetic variations. The CE marked test kits offers
laboratories a simple-to-use product which provides reliable and
accurate detection, with a rapid turnaround time. For the full
customer brochure see here:
http://www.rns-pdf.londonstockexchange.com/rns/6811M_1-2019-9-17.pdf
Lyn Rees, CEO of Yourgene, commented:
"This product launch marks a number of firsts for Yourgene. This
is the first new test kit launched since the acquisition of
Elucigene earlier this year, and is a testament to the smooth and
successful integration of the two businesses. It is also our first
product in the area of oncology, which delivers on our strategy to
expand our product portfolio and bring new products to market. This
is also our first product in the area of pharmacogenomics, an
exciting medical field that looks at how genes impact upon a
patient's response to drugs, and so we are very pleased to be
addressing a broader market within Precision Medicine."
About the Bionow Precision Medicine Conference
Elucigene DPYD is being launched today at the Bionow Precision
Medicine Conference at Citylabs 1.0 in Manchester. The conference
which brings together the UK's leading experts in the area of
Precision Medicine, an emerging area of healthcare research that
uses an individual's genetic profile to guide decisions about the
prevention, diagnosis and treatment of disease. Dr Stephen Little,
Vice Chair and Founder of Yourgene Health is speaking in a session
focused on "Precision Medicine in oncology." For more information
on the conference visit:
https://bionow.co.uk/event/Bionow012/bionow-precision-medicine-conference
Notes
1. D. Meulendijks et al./Cancer Treatment Reviews 50 (2016)
23-34
2. Cancer Research UK https://bit.ly/2kLn1uT
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
Yourgene Health plc Tel: +44 (0)161 667 1053
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / James Caithie / Ludovico
Lazzaretti
Stifel Nicolaus Europe Limited (Sole Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations) Mob: 07980 541 893 / 07584 391 303
Paul McManus / Lianne Cawthorne / 07876 741 001
/ Anna Dunphy
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate
molecular diagnostic solutions, primarily for reproductive health.
The Group's products include non-invasive prenatal tests (NIPT) for
Down's Syndrome and other genetic disorders, Cystic Fibrosis
screening tests, invasive rapid aneuploidy tests, male infertility
tests and genetic disease tests. Yourgene's commercial footprint is
already established in the UK, Europe, the Middle East, Africa and
Asia.
Our product development, research service and commercial
capabilities extend across the lifecycle of genetic test
development including regulatory submissions. Through our technical
expertise and partnerships, Yourgene Health is also extending its
genetic testing offering into oncology.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei and Singapore, and is listed on the London Stock
Exchange's AIM market under the ticker "YGEN". For more
information, visit www.yourgene-health.com and follow us on twitter
@Yourgene_Health.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCLLFIDASIDLIA
(END) Dow Jones Newswires
September 18, 2019 02:00 ET (06:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2023 to May 2024